Advisor Resource Council Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)

Advisor Resource Council bought a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 90,577 shares of the biopharmaceutical company's stock, valued at approximately $2,595,000.

A number of other institutional investors have also recently bought and sold shares of the business. Allworth Financial LP raised its position in Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares in the last quarter. Louisbourg Investments Inc. acquired a new stake in shares of Royalty Pharma in the first quarter valued at $28,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 414 shares in the last quarter. Riverview Trust Co increased its stake in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares during the period. Finally, Rakuten Securities Inc. increased its stake in shares of Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 1,003 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Trading Down 0.1%

Shares of Royalty Pharma stock traded down $0.05 during trading on Friday, hitting $34.86. 5,346,891 shares of the company were exchanged, compared to its average volume of 3,638,575. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. The firm has a market capitalization of $19.60 billion, a P/E ratio of 18.84, a price-to-earnings-growth ratio of 1.79 and a beta of 0.48. The firm's fifty day moving average price is $33.08 and its 200 day moving average price is $31.15. Royalty Pharma PLC has a 1-year low of $24.05 and a 1-year high of $35.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. The firm had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. As a group, sell-side analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 47.57%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RPRX. Morgan Stanley began coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target for the company. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Finally, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $47.33.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.